A 58-year-old woman with COPD GOLD Stage 2 is counseled on non-pharmacological interventions to reduce symptom burden and improve outcomes. All of the following measures are supported by evidence EXCEPT:

Explanation

## Non-Pharmacological Management of COPD **Key Point:** Supplemental oxygen is NOT indicated in all COPD patients. It is reserved for those with documented hypoxemia (SpO₂ ≤88% or PaO₂ ≤55 mmHg at rest, or desaturation on exertion in specific contexts) and improves mortality only in hypoxemic patients. ### Evidence-Based Non-Pharmacological Interventions | Intervention | Indication | Evidence | |--------------|-----------|----------| | Pulmonary rehabilitation | All COPD patients (especially moderate-severe) | Improves exercise capacity, dyspnea, QoL; reduces hospitalizations | | Smoking cessation | All current smokers | Only intervention that slows FEV₁ decline; reduces exacerbations | | Supplemental O₂ | Hypoxemia (SpO₂ ≤88% or PaO₂ ≤55 mmHg) | Improves survival in hypoxemic COPD; NOT for all patients | | Vaccination (flu, pneumococcal) | All COPD patients | Reduces exacerbation and hospitalization rates | **High-Yield:** The NOTT (Nocturnal Oxygen Therapy Trial) and MRC (Medical Research Council) trials demonstrated that long-term oxygen therapy improves survival ONLY in patients with resting hypoxemia (PaO₂ ≤55 mmHg or SpO₂ ≤88%). Routine oxygen in non-hypoxemic COPD does not improve outcomes and may increase mortality risk [cite:GOLD 2023]. **Clinical Pearl:** Supplemental oxygen during exercise in non-hypoxemic patients may improve exercise tolerance acutely but does not translate to long-term mortality or hospitalization benefit. **Warning:** "Oxygen improves quality of life in all COPD" is a common misconception. Oxygen is a medication with indications—not a blanket therapy.